TRIPLE NEGATIVE BREAST NEOPLASMS
Clinical trials for TRIPLE NEGATIVE BREAST NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST NEOPLASMS trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE2 • Sponsor: GV20 Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo aims to tackle tough breast cancer
Disease control Not yet recruitingThis phase 2 trial tests whether combining the targeted chemotherapy sacituzumab govitecan with the immunotherapy toripalimab works better than toripalimab plus standard chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer that is PD-L1 positive. A…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 26, 2026 15:18 UTC
-
New combo strategy takes on Hard-to-Treat breast cancer
Disease control Not yet recruitingThis phase 2 trial tests whether alternating two targeted chemotherapy drugs—sacituzumab govitecan and trastuzumab deruxtecan—can help people with HER2-low triple-negative breast cancer that has spread. About 260 participants will be randomly assigned to receive either the altern…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 26, 2026 13:20 UTC